Simon H Stertzer

Director Simon H Stertzer purchases 109,200 shares (191.1% increase) at BioCardia for $103,584 across two transactions at $0.92 and $1.00.

Simon H Stertzer, a Director at BioCardia, executed 2 purchases totaling 109,200 shares for $103,584.00, raising his holdings from 57,138 to 166,338 shares—a 191.1% increase. The purchases occurred at $0.92 (70,200 shares on 2026-06-22) and $1.00 (39,000 shares on 2026-06-23), with a blended average price of $0.95, slightly below the current price of $1.06 but -56.7% from the 52-week high of $2.45. His prior transaction history at this ticker shows mixed near-term timing: 2 of 5 prior buys at BCDA yielded positive 90-day returns (trades on 2025-09-19 and 2025-04-23 gained +16.0% and +20.5% respectively at the 90-day mark), while others underperformed, including the most recent buy on 2025-06-30 which declined -31.6% over 90 days. BioCardia's fundamentals are materially stressed—the company reported $0.00 revenue (latest quarter), a net loss of $-2,259,000.00, and -100.0% annual revenue growth, with a market capitalization of only $12,057,207.44. The substantial share accumulation by a director into a loss-making, revenue-depleted micro-cap warrants investor scrutiny of both the director's conviction on the turnaround thesis and the company's capital adequacy and operational path forward.

Director STERTZER SIMON H bought 398,400 BCDA shares at $1.25; stock down -26.2% in 30 days, -37.3% in 90 days; company unprofitable with -87.8% revenue decline

Director Stertzer purchased 398,400 shares worth $498,000.00 on 2025-09-19, more than tripling his position from 192,654 shares to 591,054 shares. This acquisition occurs within a cluster of 2 other insider purchases in the past 14 days. However, the timing relative to recent price action raises concerns: BCDA shares have declined -26.2% over the prior 30 days and -37.3% over the prior 90 days from the purchase date, and the stock currently trades at $1.41, down -55.1% from its 52-week high of $3.14. Compounding this context, the company reported zero revenue in the latest quarter, a net loss of $-2,049,000.00, and annual revenue contraction of -87.8%, with negative full-year net income. Stertzer's prior trades at BCDA show mixed timing: 1 of 4 prior measurable buys achieved a positive 90-day return (the April 2025 purchase), while 3 of 4 resulted in declines at the 90-day mark. The cluster pattern and large purchase size warrant monitoring, but the company's deteriorating fundamentals and the director's uneven execution on prior BCDA trades indicate execution risk.

Director buys 72,289 shares of BCDA at $2.08 (-48.3% from 52-week high); 4 prior BCDA buys show 0 of 3 measurable trades profitable at 90 days.

Simon Stertzer purchased 72,289 shares at $2.08, expanding his holdings by 60.1% to 192,654 shares. The purchase occurs when the stock trades -48.3% from its 52-week high of $4.02, and the company is fundamentally troubled: latest quarter revenue was $0.00, annual revenue contracted -87.8%, and the business posted a net loss of $-2.7M over its most recent full fiscal year. His prior four buys at BCDA reveal a pattern of poor entry timing—three have measurable 90-day outcomes, none of which returned positive results; the buy on 2025-03-05 declined -11.0% at 90 days, the buy on 2025-03-04 declined -1.7%, and the buy on 2025-03-03 declined -6.1%. The current transaction occurs alongside 3 other insider buys within 14 days, forming a cluster pattern. This converging signal—a director accumulating into a distressed valuation where his own prior trades show no success in timing reversals—requires scrutiny into whether these concurrent purchases reflect genuine confidence in value recognition or simply mechanical buying into a collapsing stock.

Director Stertzer bought 104,986 shares of BCDA at $1.90 on 2025-04-23 ($200.0K); stock down 22.8% in 30 days, 67.6% from 52-week high.

Director Simon H. Stertzer purchased 104,986 shares at $1.90, increasing his holdings by 682.7% to 120,365 shares total. The timing of this purchase is noteworthy: BCDA stock has declined 22.8% over the past 30 days and trades 67.6% below its 52-week high of $6.09, suggesting Stertzer bought into a depressed price. The company's fundamentals are concerning—revenue was $0.00 in the latest quarter, net income was negative $1,737,000, and annual revenue has contracted 87.8% year-over-year, with a market cap of only $9,219,609.85. Stertzer's prior purchases at BCDA over March 2025 have been followed by negative 30-day returns (-18.0%, -8.7%, -1.3%), and across his cross-ticker track record, his 3 prior open-market buys averaged -9.3% 30-day returns with a 0% well-timed rate at the 90-day mark. A cluster pattern is present: 5 other insiders also bought within the past 14 days, which may warrant additional scrutiny given the company's deteriorating financial position.

BCDA Director Stertzer buys 1,000 shares at $2.45; stock down -61.6% from 52-week high of $6.83.

Simon H Stertzer, a Director, purchased 1,000 shares of BioCardia on 2025-03-05 at $2.45, adding to a position that grew from 56,138 to 57,138 shares. This marks a consecutive purchase—the insider also bought on 2025-03-04 and 2025-03-03—within a narrow three-day window. The stock trades at $2.62, down -61.6% from its 52-week high of $6.83, though it has recovered +23.6% over the past 90 days. Fundamentally, the company remains unprofitable with a net loss of $-1,737,000.00, zero revenue in the latest quarter, and annual revenue contraction of -64.7%. Investors should note the rapid series of purchases at depressed levels alongside deteriorating financial metrics and an extremely small market cap of $12,010,826.70.

Director Simon H. Stertzer buys 38,289 shares at $2.30 over 2 days; stake grows 214.5% to 56,138 shares

On 2025-03-03 and 2025-03-04, Director Simon H. Stertzer purchased a total of 38,289 shares at $2.30, increasing his holdings from 17,849 to 56,138 shares—a 214.5% increase in position size executed across two consecutive trading days. The purchase totaling $88,064.70 occurred in a company with deeply challenged fundamentals: BioCardia reported zero revenue in the latest quarter, a net loss of $-1,737,000.00 for the fiscal year, and a -64.7% annual revenue decline, resulting in a market cap of just $11,644,083.90. While the stock has recovered 17.6% over the past 90 days and currently trades at $2.54, the company remains unprofitable and the director's accumulation follows no established pattern of well-timed prior buys at this ticker. This represents a substantial commitment at distressed valuations without measurable track record evidence of successful timing at BCDA.